CONSEGNA PHARMA INC

Pittsburgh, PA · Founded 2017 · Biotech · Private

Long-acting ketamine microparticle formulation (CP110) for sustained drug delivery in substance use disorder treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · consegnapharma.com

Sector: Biotech
Headquarters: Pittsburgh, PA
Founded: 2017
Latest Form D: $20K, Sep 2017
Total capital: $5.1M

Federal grants: $3.8M; 8 awards · 2019–2025; Rank in peer group#141 of 517
Private capital raised: $20K; 1 Form D · last Sep 2017; 109 months since last filing
Federal contracts: $1.3M; 2 awards · Defense; Rank in Biotech#170 of 4373
Granted patents: 0; 5 pending

Capital timeline

Latest events

Aug 2025Federal grantHealth and Human S · Phase II · IND-enabling development of a long-duration antagonist to treat opioid overdose$378K
Aug 2024Federal grantHealth and Human S · Phase II · IND-enabling development of a long-duration antagonist to treat opioid overdose$837K
Sep 2023Federal grantHealth and Human S · Phase II · IND-enabling development of a long-duration antagonist to treat opioid overdose$1.3M
Aug 2023Federal grantHealth and Human S · Phase I · Long-acting injectable ketamine for improved substance use disorder (SUD) treatment without dissociative effects.$327K
Aug 2023Federal grantHealth and Human S · Phase I · Long-acting injectable ketamine for improved substance use disorder (SUD) treatment without dissociative effects.$327K
Dec 2021Federal contractDefense · Phase II - Base Period$1.1M
Feb 2020Federal contractDefense · Army SBIR Phase I$167K
Sep 2017Private capital raisedForm D · SEC · 1st filing$20K

Show 3 earlier federal awards

Dec 2019Federal grantHealth and Human S · Phase I · Prevention of renarcotization from synthetic opioids$87K
Sep 2019Federal grantHealth and Human S · Phase I · Prevention of renarcotization from synthetic opioids$305K
Sep 2019Federal grantHealth and Human S · Phase I · Prevention of renarcotization from synthetic opioids$218K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 517 peers

Line = median

Biotech · Molecule

Federal grants#141 · top 27%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Lawrence J. ZanaResearcherExecutive Officer, Director, PromoterLinked by $327K in grants as PI

What it has protected

USPTO · 0 granted of 5

Jul 13, 2023PendingLong Acting Opioid AntagonistsUSPTOApplication 18153838
Dec 22, 2022PendingLong Acting Nmda AntagonistsUSPTOApplication 17776691
Jul 4, 2019PendingLong Acting Opioid AntagonistsUSPTOApplication 16235021

Show all 5 patent records

Long Acting Opioid AntagonistsJul 13, 2023 · Application 18153838Pending
Long Acting Nmda AntagonistsDec 22, 2022 · Application 17776691Pending
Long Acting Opioid AntagonistsJul 4, 2019 · Application 16235021Pending
Long Acting Nmda AntagonistsApplication PCTUS2020070788Pending
Long Acting Opioid AntagonistsApplication PCTUS2018067847Pending

AM BIOTECHNOLOGIES, LLCSimilar federal contract value in Biotech · $1.3M in contracts
CYTOBANK, INC.Similar federal contract value in Biotech · $1.3M in contracts
MIRIMUS, INC.Similar federal contract value in Biotech · $1.3M in contracts
MYEXPOSOME INCSimilar federal contract value in Biotech · $1.3M in contracts
INSILICOM LLCSimilar federal contract value in Biotech · $1.3M in contracts
EVESTRA, INC.Similar federal contract value in Biotech · $1.2M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.